China’s National Medical Products Administration (NMPA) in November announced the creation of a platform to collect information related to all active pharmaceutical ingredients (APIs) in circulation in the country.
The new platform will allow NMPA, which drafts laws and regulations for drugs, medical devices, and cosmetics, to better supervise and manage the use of APIs in China.
Domestic and overseas API manufacturers are being asked by the agency to provide production and supply information on a quarterly basis of all APIs used in products they market in China, including essential and scarce drugs.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.